(R)-2-((1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)amino)-N-ethyl-N-methylpropanamide

ID: ALA4537603

PubChem CID: 155548362

Max Phase: Preclinical

Molecular Formula: C16H24N6O2

Molecular Weight: 332.41

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CCN(C)C(=O)[C@@H](C)Nc1nc2c(cnn2C2CCCC2)c(=O)[nH]1

Standard InChI:  InChI=1S/C16H24N6O2/c1-4-21(3)15(24)10(2)18-16-19-13-12(14(23)20-16)9-17-22(13)11-7-5-6-8-11/h9-11H,4-8H2,1-3H3,(H2,18,19,20,23)/t10-/m1/s1

Standard InChI Key:  JNQGAYSHKJDZCY-SNVBAGLBSA-N

Molfile:  

 
     RDKit          2D

 24 26  0  0  0  0  0  0  0  0999 V2000
   42.8695   -2.0471    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   42.8695   -2.8684    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   43.5748   -3.2729    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   43.5748   -1.6303    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   44.2842   -2.0471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   44.2887   -2.8649    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.0680   -3.1121    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   45.5469   -2.4471    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   45.0608   -1.7915    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.3313   -3.8888    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   44.8505   -4.5566    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.3386   -5.2193    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   46.1186   -4.9583    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   46.1098   -4.1371    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   42.1583   -3.2780    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   41.4459   -2.8705    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   40.7346   -3.2801    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   41.4447   -2.0492    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   40.0222   -2.8725    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   40.7358   -4.1014    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   43.5748   -0.8089    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   40.0210   -2.0512    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.3109   -3.2822    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.3121   -4.1035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  1  4  1  0
  2  3  2  0
  3  6  1  0
  5  4  1  0
  5  6  2  0
  6  7  1  0
  7  8  1  0
  8  9  2  0
  9  5  1  0
 10 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 10  1  0
  7 10  1  0
  2 15  1  0
 15 16  1  0
 16 17  1  0
 16 18  1  1
 17 19  1  0
 17 20  2  0
  4 21  2  0
 19 22  1  0
 19 23  1  0
 23 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4537603

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 332.41

Molecular Weight (Monoisotopic): 332.1961

AlogP: 1.51

#Rotatable Bonds: 5

Polar Surface Area: 95.91

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 10.56

CX Basic pKa: 1.75

CX LogP: 0.69

CX LogD: 0.69

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.87

Np Likeness Score: -1.54

References

1. Wu Y, Zhou Q, Zhang T, Li Z, Chen YP, Zhang P, Yu YF, Geng H, Tian YJ, Zhang C, Wang Y, Chen JW, Chen Y, Luo HB..  (2019)  Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.,  62  (8): [PMID:30916555] [10.1021/acs.jmedchem.8b01041]

Source

Source(1):

• Scientific Literature